Prior to the most recent expansion of the existing license agreement, Bristol-Myers Squibb had a non-exclusive license to use prior versions of MorphoSys’ HuCAL library and the AutoCAL system, which is MorphoSys’ established system for fully automated high-throughput antibody generation, installed at one of Bristol-Myers Squibb’s facilities in the US
Bristol-Myers Squibb currently applies MorphoSys’ proprietary antibody technology in its pharmaceutical discovery programs for target characterization and validation. In addition, it has an option to further develop promising antibody candidates arising from these programs as therapeutics and diagnostics.
“Bristol-Myers Squibb has now decided to upgrade to the most advanced version of our antibody library, HuCAL GOLD,” commented Dr Simon Moroney, CEO, MorphoSys AG. “We are delighted that Bristol-Myers Squibb continues to value our expertise in antibody development, as well as in supporting its target characterization and validation programs.”